tb-500 mastery course
Unit 1 of 12 -- free

TB-500: the thymosin beta-4 fragment

how a fragment of a thymus hormone became one of the most discussed repair peptides in research and athletics

The Thymosin Beta-4 Fragment

In 1966, Allan Goldstein at the Albert Einstein College of Medicine isolated a family of small thymus-gland proteins. One member, thymosin beta-4 (TB4), turned out to be the most abundant intracellular peptide in nearly every nucleated human cell -- holding 40-50% of total actin as monomers.

TB-500 is the synthetic 43-amino-acid TB4 sequence, built around the LKKTET motif that drives actin binding and tissue repair. It has been studied in animal models for wound healing, cardiac repair, and cell migration, and was banned by WADA in 2013.

0.1-0.5 mM
cellular concentration of TB4
70-80%
of the beta-thymosin pool
43 aa
canonical TB4 length
2013
added to WADA prohibited list

what this course covers

01 Discovery & Overview free 02 Molecular Structure paid 03 Actin Biology paid 04 Cell Migration & Angiogenesis paid 05 Anti-Inflammatory Mechanisms paid 06 Wound Healing & Tissue Repair paid 07 Cardiac & Neurological Research paid 08 Clinical Trials & Evidence paid 09 Dosing & Administration paid 10 Safety & Risk Profile paid 11 Regulatory Landscape paid 12 Final Exam & Certification paid

Thymosin Family Origins

From thymus extract to a family of 43 beta-thymosins found in nearly every cell in the body.

Goldstein's thymosin fraction 5 was a crude calf-thymus extract. Researchers separated it into three families by isoelectric point: alpha, beta, and gamma.

family length discovery primary function representative member
alpha ~28 aa 1977 immune modulation thymosin alpha-1 (Zadaxin)
beta ~43 aa 1981 G-actin sequestration thymosin beta-4 (TB4 / TB-500)
gamma variable 1980s minor / uncharacterized thymosin gamma (rarely studied)
TB4 is the dominant beta-thymosin and binds G-actin 1:1 (Kd ~0.7 microM, Safer 1991). Commercial TB-500 reproduces the 43-residue TB4 sequence, though a 17-residue LKKTET-only fragment is sometimes sold under the same name.
43
amino acids (TB4)
1966
Goldstein thymosin discovery
~4,921
daltons molecular weight
LKKTET
active motif sequence

The LKKTET Motif

Six amino acids that drive actin binding, cell migration, and wound repair.

interactive discovery timeline
L
Leu 17
K
Lys 18
K
Lys 19
T
Thr 20
E
Glu 21
T
Thr 22
what it does: the six-residue motif at positions 17-22 is the minimum fragment required for G-actin sequestration. binding a monomer blocks spontaneous polymerization. Safer et al. (1997) showed that swapping either lysine (K18 or K19) for alanine dropped actin-binding affinity by more than 80% -- those positive charges are the essential contacts on actin's subdomain 1.
why it matters: actin dynamics drive cell movement. in a motile cell the G-actin to F-actin ratio sits near 1:1, and TB4 holds roughly 40-50% of total actin in monomeric form (Pollard & Borisy, 2003). beyond binding, the LKKTET region promotes angiogenesis, suppresses NF-kB inflammation, and activates muscle satellite cells in animal models -- Malinda et al. (1999) saw endothelial migration at concentrations as low as 1 nM.
Ac-SDKP fragment
N-terminal residues 1-4 of TB4. Independent bioactivity as an endogenous anti-fibrotic factor.
POP releases it
Prolyl oligopeptidase cleaves Ac-SDKP from full-length TB4 in vivo.
ACE degrades it
ACE inhibitor drugs raise circulating Ac-SDKP, possibly contributing to their cardioprotective effect (Cavasin 2004).

Tissue Repair Mechanisms

An overview of the four primary pathways through which TB-500 is proposed to promote healing.

Educational content only. This unit describes clinical trial data and is not medical advice. Consult a licensed physician before considering any investigational compound.

actin regulation
sequesters G-actin monomers in 1:1 complex, freeing them on demand for cell movement.
animal: ~100-200 microM buffer per cell
cell migration
activates ILK/PINCH/parvin -- Akt signaling drives directed movement to injury.
animal: Bock-Marquette 2004, Nature
angiogenesis
upregulates VEGF and triggers endothelial tube formation for new vessels.
animal: ~3-fold CAM vessels (Grant 1999)
anti-inflammatory
blocks NF-kB nuclear translocation and lowers TNF-alpha, IL-1beta, IL-6.
animal: ~45% TNF drop (Sosne 2007)
4
primary repair pathways
0
FDA-approved uses
2013
WADA ban year
Tier 3
evidence level
Education only. TB-500 is not FDA-approved for human use and is banned by WADA. All cited data is from animal or in-vitro work unless noted otherwise.

2026 update: A June 2026 Investigative Ophthalmology & Visual Science study (Ebrahim et al.) found that adjunctive thymosin beta-4 combined with ciprofloxacin in a mouse model of bacterial corneal infection restored corneal nerve density to levels matching uninfected controls and markedly improved visual acuity and contrast sensitivity — superior to antibiotic treatment alone — adding ophthalmic nerve regeneration during active infection as a newly documented research application for TB4. (PMID 42283548)

Research Timeline

Four decades of research, from thymus immunology to tissue repair and the equine racing controversies that brought TB-500 into public awareness.

1966 - 1980
thymosin discovery era
Goldstein isolates thymosin fraction 5 from calf thymus. interest is purely immunological -- TB4 is noted as most abundant but filed as an immune peptide (Goldstein et al., 1977).
1981 - 1995
the actin connection
Safer et al. (1991) reframe TB4 as a cytoskeletal regulator, not an immune peptide. NMR and crystallography map the actin-binding interface and pin down the LKKTET motif.
1996 - 2008
tissue repair & cardiac
Malinda 1999 shows dermal wound healing in aged mice. Bock-Marquette 2004 publishes the landmark Nature paper on cardioprotection via the ILK/Akt survival pathway.
2008 - 2015
equine racing & WADA
australian trainers use TB-500 for racehorse recovery. high-profile doping cases prompt WADA to explicitly name thymosin beta-4 under section S2 in the 2013 prohibited list update.
2016 - present
consumer peptide market
biohacking demand explodes around the BPC-157 "wolverine stack". RegeneRx's RGN-259 completes Phase 2 for dry eye, but as of 2026 no systemic TB4 product is approved anywhere.

The WADA Ban

Why TB-500 was added to the World Anti-Doping Agency prohibited list in the 2013 update, and the regulatory landscape that followed.

Educational content only. This unit describes clinical trial data and is not medical advice. Consult a licensed physician before considering any investigational compound.

WADA classifies thymosin beta-4 and all its fragments — including TB-500 — under section S2 (peptide hormones, growth factors, related substances, and mimetics), the same prohibited category as growth hormone and erythropoietin. The ban applies in-competition and out-of-competition, meaning a confirmed positive at any point in the year carries the same sanctions regardless of therapeutic intent. Australian horse-racing investigations between 2008 and 2012 documented systematic use of TB-500 in racehorses for soft-tissue recovery, and those doping cases were a direct catalyst for the explicit 2013 inclusion of TB4 and its fragments in the prohibited list.

2013
WADA section S2 -- explicitly names TB4 and fragments
0
FDA approvals -- no systemic indication in any jurisdiction
none
EMA authorization -- no europe-wide human-use approval
S4
australia schedule 4 -- prescription-only, research chemical
Not a legitimate therapeutic anywhere in 2026: WADA-prohibited (section S2), no FDA approval, no EMA authorization. Regulatory unit covers detection windows, S2 scope, and the equine-racing cases that accelerated the ban.

honest evidence ceiling

TB-500's research base is wide but shallow. here is exactly where the evidence sits and where it stops.

Educational content only. This unit describes clinical trial data and is not medical advice. Consult a licensed physician before considering any investigational compound.

solid (in vitro)
actin sequestration biochemistry is thoroughly characterized. Kd, stoichiometry, and binding chemistry are confirmed by X-ray crystallography and NMR in multiple labs.
moderate (animal)
wound healing, cardiac, and neurological effects replicated across rodent and porcine models by independent groups. consistent direction but variable magnitudes across studies.
weak (single human path)
only the ophthalmic RGN-259 program has reached Phase 2 in humans. systemic injectable TB-500 has zero completed RCTs in people.
missing (human systemic)
no human pharmacokinetic data for subcutaneous dosing, no human dose-response curve, no long-term safety data. the gap between animal promise and human proof is large.
the animal data is compelling but does not predict human outcomes. approximately 90% of drugs that succeed in animal models fail in human trials. TB-500 has not cleared that hurdle for any systemic indication.

key terms

core vocabulary for this course.

T thymosin beta-4 (TB4) peptide
the endogenous 43-amino-acid peptide produced in nearly every nucleated human cell. TB-500 is the synthetic version of the full TB4 sequence. TB4 is the most abundant intracellular peptide of its family, holding 40-50% of total actin as monomers.
G G-actin protein
globular actin -- the unpolymerized monomer form of actin that TB4 sequesters in a 1:1 complex. G-actin is the building block of F-actin filaments. TB4's core function is holding G-actin in reserve so cells can deploy it rapidly when needed for movement or repair.
L LKKTET motif sequence
the six-residue sequence at positions 17-22 of TB4 that directly contacts G-actin. LKKTET is the minimum fragment required for actin sequestration. the two lysine residues (K18 and K19) form critical electrostatic contacts with actin subdomain 1; replacing either with alanine drops binding affinity by over 80%.
W WADA S2 prohibition regulation
since 2013, the World Anti-Doping Agency explicitly lists thymosin beta-4 and its fragments under section S2 (peptide hormones, growth factors, and related substances). any competitive athlete subject to WADA rules who uses TB-500 faces disqualification and a multi-year ban, regardless of therapeutic intent.
I ILK pathway mechanism
integrin-linked kinase -- the signaling hub that TB4 activates to drive cell migration and survival. ILK forms a trimeric complex with PINCH and parvin at focal adhesions, then phosphorylates Akt to promote anti-apoptotic and pro-migratory signaling. this pathway is how TB4 reaches beyond actin biology into tissue repair.
A Ac-SDKP fragment
a four-amino-acid fragment (N-acetyl-seryl-aspartyl-lysyl-proline) cleaved from TB4's N-terminus by prolyl oligopeptidase. Ac-SDKP drives angiogenesis and reduces fibrosis independently of the full-length peptide. ACE inhibitors raise circulating Ac-SDKP, possibly contributing to their cardioprotective effects.

The Animal Evidence

A broad overview of what animal studies have shown -- and the critical gap where human data should be.

Educational content only. This unit describes clinical trial data and is not medical advice. Consult a licensed physician before considering any investigational compound.

cardiac repair animal

Bock-Marquette 2004: ~50% infarct-size reduction in mouse coronary ligation. Hinkel 2015: improved cardiac function in a porcine ischemia model with intracoronary delivery.

dermal wound healing animal

Philp 2004: 25-30% faster full-thickness closure in db/db diabetic mice, with increased keratinocyte migration and collagen deposition.

corneal repair phase 2

Sosne 2002-2015: corneal re-epithelialization after injury. Led to RegeneRx's RGN-259 program, the most advanced TB4 therapeutic in development.

neurological animal

Xiong 2012: improved recovery after TBI in rats, with neurogenesis in the dentate gyrus. Morris 2014: improved outcomes in an EAE rat model (multiple sclerosis).

50+
animal studies published
1
Phase 2 clinical program
Tier 3
evidence level
6+
tissue types studied
the evidence gap: while the cardiac and ophthalmological data are compelling, the same caveat applies as with any preclinical compound: approximately 90% of drugs that show promise in animal models fail in human clinical trials. TB-500's effects in humans remain largely unvalidated by rigorous clinical data. the only formal clinical program (RegeneRx's RGN-259 for dry eye) uses topical rather than systemic delivery, and its results cannot be extrapolated to the systemic uses that drive consumer demand.

What's Ahead

12 units organized into 4 learning phases, from molecular foundations to real-world context.

12 units
quizzes & exercises each
~6 hours
estimated completion
50+ sources
primary research cited
80% pass
score for certification
certificate
specialist credential
skills you'll build
peptide pharmacology
literature evaluation
clinical trial analysis
safety risk assessment
foundations
units 1-3
mechanisms
units 4-6
evidence
units 7-9
context
units 10-12
phase 1
foundations
Unit 1 -- Discovery & Overview Unit 2 -- Molecular Structure Unit 3 -- Actin Biology
phase 2
mechanisms
Unit 4 -- Cell Migration & Angiogenesis Unit 5 -- Anti-Inflammatory Mechanisms Unit 6 -- Wound Healing & Tissue Repair
phase 3
evidence
Unit 7 -- Cardiac & Neurological Research Unit 8 -- Clinical Trials & Evidence Unit 9 -- Dosing & Administration
phase 4
context
Unit 10 -- Safety & Risk Profile Unit 11 -- Regulatory Landscape Unit 12 -- Final Exam & Certification
every claim is traced to its primary research source and every limitation is clearly stated. this course is designed to give you the knowledge to evaluate TB-500 claims critically -- not to promote its use.

Knowledge Check

Test what you've learned about TB-500's origins and research landscape.

Practice Exercises

Reinforce your understanding with interactive exercises.

Next Unit

Molecular Structure